This Review Article provides a multi-stakeholder view on the current status of neoadjuvant
therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs).
In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

A widespread approach to modern cancer therapy is to identify a single oncogenic driver
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-…

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell RNA …

Introduction Central nervous system (CNS) metastases are common in non–small cell lung
cancer (NSCLC), yet clinical trials of new drugs in advanced NSCLC have varying inclusion …

Background Rearranged during transfection (RET) gene fusions are a validated target in
non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and …

Background Current guidelines recommend that patients with peripheral arterial disease (
PAD ) cease smoking and be treated with aspirin, statin medications, and angiotensin‐…

… CE McCoach is a consultant/advisory board member for Takeda and Guardant Health. A. Le
… Writing, review, and/or revision of the manuscript: CE McCoach, A. Le, KD Davies, PA Bunn, …

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC)
enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung …

… CE McCoach is a consultant/advisory board member for Guardant Health and Takeda.
CM Blakely is a consultant/advisory board member for Jazz Pharmaceuticals, and reports …